2. UroToday Home
  3. Actionable Clinical Data
  4. NMIBC with CIS: Evidence, Practice & Emerging Research
  5. Articles
  6. Conferences

EAU 2026

EAU 2026

EAU 2026: A Phase II, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a game changer session and a presentation by Dr. Brian Chapin discussing results from a phase II, randomized, controlled trial of best systemic therapy versus best systemic therapy + definitive treatment of the primary tumor in metastatic prostate cancer. Local therapy in men with de novo metastatic (M1) prostate cancer is evolving and somewhat conflicting based on the current randomized clinical trials:

EAU 2026: Adjuvant Pembrolizumab + Belzutifan for Clear Cell RCC: Primary and Exploratory Efficacy Outcomes from the Phase 3 LITESPARK-022 Study

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a game changer session and a presentation by Dr. Thomas Powles discussing primary and exploratory efficacy outcomes from the phase 3 LITESPARK-022 study assessing adjuvant pembrolizumab + belzutifan for clear cell RCC. Adjuvant pembrolizumab improved disease free survival and overall survival versus placebo in the phase 3 KEYNOTE-564 trial.1,2 However, efficacy may be further improved with combination therapy in this setting, given that ~40% of patients treated with adjuvant pembrolizumab experience recurrence or death within 5 years of nephrectomy. Belzutifan is a potent, selective HIF-2alpha inhibitor with established efficacy in patients with advanced RCC treated with prior immunotherapy and VEGFR-TKI therapy.3 The double-blind phase 3 LITESPARK-022 trial evaluated pembrolizumab + belzutifan versus pembrolizumab + placebo as adjuvant therapy in patients with clear cell RCC at increased risk of recurrence post nephrectomy.

EAU 2026: Discussant: Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a game changer session and a discussant presentation by Dr. Markus Graefen discussing the results from a phase II, randomized, controlled trial of best systemic therapy versus best systemic therapy with definitive treatment of the primary tumor in metastatic prostate cancer. In this randomized clinical trial, there was no benefit in progression free survival or overall survival for the addition of local therapy to best standard therapy in men with de novo M1 prostate cancer. One specific feature of this study was that patients and treating physicians could choose the type of local therapy after randomization to the local therapy group.

EAU 2026: Discussant: The EV-304 Paradigm Shift

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a game changer session and a discussant presentation by Dr. Ashish Kamat discussing pathological and surgical outcomes in KEYNOTE-B15/EV-304, assessing neoadjuvant and adjuvant enfortumab vedotin + pembrolizumab for patients with muscle invasive bladder cancer who are eligible for cisplatin. Previously presented at ASCO GU 2026, Dr. Galsky reported that KEYNOTE-B15/EV-304 met its primary endpoint of improving event free survival, with a median not reached (95% CI not reached to not reached) for enfortumab vedotin + pembrolizumab and 48.5 months (95% 43.3 to not reached) for cisplatin + gemcitabine (HR 0.53, 95% CI 0.41-0.70; p < 0.0001). The 12 month event free survival rate for enfortumab vedotin + pembrolizumab was 86.0% versus 75.4% for cisplatin + gemcitabine, and the 24 month rate was 79.4% for enfortumab vedotin + pembrolizumab versus 66.2% for cisplatin + gemcitabine:

EAU 2026: PRIMARY2 – Impact of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Non-Suspicious Findings on mpMRI: A Multi-Center, Phase III, Randomized Trial

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a game changer session and a presentation by Dr. James Buteau discussing results from the PRIMARY2 phase 3 trial assessing the impact of 68Ga-PSMA-11 PET/CT in the diagnosis of prostate cancer in men with equivocal or non-suspicious findings on mpMRI. Across guidelines, multi-parametric MRI is recommended for men with clinical suspicion of significant prostate cancer. Those with PIRADS 2 or 3 lesions often undergo prostate biopsy for high clinical suspicion, but have a low likelihood of significant prostate cancer on biopsy, and high likelihood of insignificant prostate cancer. Previously, the PRIMARY trial demonstrated that 68Ga-PSMA-11 PET/CT pre-biopsy improved negative predictive value for significant prostate cancer compared to MRI alone:1

EAU 2026: Neoadjuvant and Adjuvant Enfortumab Vedotin + Pembrolizumab for Patients with Muscle Invasive Bladder Cancer Who Are Eligible for Cisplatin: Pathological and Surgical Outcomes in KEYNOTE-B15

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a game changer session and a presentation by Dr. Yohann Loriot discussing pathological and surgical outcomes in KEYNOTE-B15, assessing neoadjuvant and adjuvant enfortumab vedotin + pembrolizumab for patients with muscle invasive bladder cancer who are eligible for cisplatin. The randomized phase 3 KEYNOTE-B15/EV-304 study previously demonstrated that neoadjuvant and adjuvant enfortumab vedotin + pembrolizumab significantly improved event-free survival, pathological complete response rate, and overall survival versus neoadjuvant cisplatin + gemcitabine in patients with muscle invasive bladder cancer eligible for cisplatin-based therapy and radical cystectomy + pelvic lymph node dissection. At EAU 2026, Dr. Loriot and colleagues reported the pathological and surgical outcomes from the study.

EAU 2026: Discussant - PRIMARY2 – Impact of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Non-Suspicious Findings on mpMR

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a game changer session and a discussant presentation by Dr. Jochen Walz discussing “PRIMARY2 – Impact of 68Ga-PSMA-11 PET/CT in the diagnosis of prostate cancer in men with equivocal or non-suspicious findings on mpMRI: A multi-center, phase III, randomized trial.” The current EAU guidelines recommend performing an MRI before prostate biopsy in men with suspected organ confined disease (Strength: Strong), with the following additional recommendations:

EAU 2026: TMT for MIBC: Radiation, Responsibility, and Recurrences -- Who Manages the Fallout, and How? Debater 1: Radiation Toxicity Is Real and Its Urologists Who Manage the Consequences

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a rapid fire debate session on common problems and controversies in bladder cancer moderated by Drs. Ashish Kamat and Arnulf Stenzl, and a presentation by Dr. Antoine van der Heijden discussing radiation toxicity after trimodal therapy for muscle invasive bladder cancer and the role of the urologist in managing the consequences.

EAU 2026: TMT for MIBC: Radiation, Responsibility, and Recurrences -- Who Manages the Fallout, and How? Debater 2: Toxicity Happens but Is Manageable -- Radiation Oncologists Can and Should Take Responsibility

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a rapid fire debate session on common problems and controversies in bladder cancer, moderated by Drs. Ashish Kamat and Arnulf Stenzl, and a presentation by Dr. Neha Vapiwala discussing radiation toxicity after trimodal therapy for muscle invasive bladder cancer and that radiation oncologists can and should take responsibility.

Co-PSMA Data Presented at EAU Annual Congress 2026 with Manuscript Accepted for Publication in the European Urology Journal

Details
Highlights

  • Oral presentation on key results from the Co-PSMA (NCT06907641)1 Investigator-Initiated Trial (IIT) was delivered by Prof Louise Emmett (St Vincent’s Hospital Sydney) at the European Association of Urology (EAU) Congress 2026 on the 16th of March 2026 in London, UK.2
  • Co-PSMA trial data has also been accepted for publication in the prestigious European Urology, the official journal of EAU, with an impressive impact factor of 25.2.
  • Clarity’s 64Cu-SAR-bisPSMA (24-hour imaging) demonstrated considerable improvement in diagnostic performance in a head-to-head comparison with standard-of-care (SOC) 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) in 50 patients with biochemical recurrence (BCR) of prostate cancer with low prostate-specific antigen (PSA; 0.2 – 75 ng/mL) who were candidates for curative salvage therapy following radical prostatectomy.
  • The study’s primary endpoint was to assess the difference in mean per-patient lesion between 64Cu-SAR-bisPSMA and 68Ga-PSMA-11. Key secondary endpoints included evaluation of diagnostic accuracy against composite reference standard and patient management impact.
  • Mean per-patient lesion was higher for 64Cu-SAR-bisPSMA (24-hour imaging) vs. 68Ga-PSMA-11 (1.26 vs. 0.48, respectively), difference: 0.78 (95% confidence interval [CI]: 0.52 – 1.04), ratio 2.63 (95% CI: 1.64 – 4.20) (p <0.0001).
  • Next-day imaging with 64Cu-SAR-bisPSMA, compared with 68Ga-PSMA-11, identified a greater number of total lesions (63 vs. 24, respectively). The biggest difference in lesion detection between the tracers was in the prostate fossa and in lymph nodes. 64Cu-SAR-bisPSMA also resulted in a higher number of trial participants with a positive scan compared to 68Ga-PSMA-11 (78% vs. 36%, respectively).
  • 64Cu-SAR-bisPSMA (24-hour imaging) demonstrated a higher true positive rate (71% vs. 29%) and lower false negative rate (21% vs. 65%) than 68Ga-PSMA-11.
  • 64Cu-SAR-bisPSMA next-day imaging resulted in management change in 44% (22/50) of trial participants, with the majority changing from surveillance to targeted radiotherapy.
  • Co-PSMA trial data, combined with Phase II COBRA and anticipated results from a pivotal Phase III AMPLIFY study, are intended to be submitted to the United States (US) Food and Drug Administration (FDA) for a market authorisation of 64Cu-SAR-bisPSMA in patients with BCR of prostate cancer.
Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results from the Co-PSMA (NCT06907641)1 IIT were presented by Prof Louise Emmett (St Vincent’s Hospital Sydney) in an oral session at EAU Congress 2026, Europe’s largest urological conference, on the 16th March in London, UK.2 The study data has also been accepted for publication in European Urology, the official journal of EAU, with an impressive impact factor of 25.2.

EAU 2026: What Do You Need for Decision-making in mHSPC in 2026?

Details

(UroToday.com) The European Association of Urology (EAU) 2026 Annual Congress was host to a thematic session jointly organized by the Advanced Prostate Cancer Consensus Conference (APCCC) and the EAU. Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, focusing on how contemporary therapeutic choices in metastatic hormone-sensitive prostate cancer (mHSPC) should extend beyond disease volume alone and instead incorporate access to therapy, patient fitness, age, comorbidity burden, cognition, skeletal health, cardiovascular status, and drug-drug interactions.

EAU 2026: Macroscopic Local Relapse after RP in the Context of High-risk nmHSPC

Details

(UroToday.com) The European Association of Urology (EAU) 2026 Annual Congress was host to a thematic session jointly organized by the Advanced Prostate Cancer Consensus Conference (APCCC) and the EAU. Dr. Chris Parker presented on the management of macroscopic local relapse after radical prostatectomy in the setting of high-risk non-metastatic hormone-sensitive prostate cancer (nmHSPC), focusing on three practical questions: what radiotherapy dose should be used, what should be included in the radiotherapy target volume, and what role systemic therapy should play.

Photocure: Trials in Progress Presented at the European Association of Urology (EAU) 2026 Congress Aim to Enable a More Personalized Bladder Cancer Care Pathway

Details
Reno, Nevada (UroToday.com) -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two “trial in progress” presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate different stages of the diagnostic pathway, addressing data gaps to improve individual patient care and outcomes.

EAU 2026: Presentation of APCCC 2024/2025 Results on Synchronous High-volume mHSPC & Voting

Details

(UroToday.com) The European Association of Urology (EAU) 2026 Annual Congress was host to an advanced prostate cancer session hosted jointly by the Advanced Prostate Cancer Consensus Conference (APCCC) and the EAU. Dr. Fabio Turco presented results from the consensus expert voting on high volume, metastatic hormone-sensitive prostate cancer (mHSPC) during the 2024/2025 APCCC meeting and queried the audience regarding their preferred management options for select patient scenarios.1

EAU 2026: Presentation of APCCC 2024/2025 Results on High-risk nmHSPC & Voting

Details

(UroToday.com) The European Association of Urology (EAU) 2026 Annual Congress was host to an advanced prostate cancer session hosted jointly by the Advanced Prostate Cancer Consensus Conference (APCCC) and the EAU. Dr. Aurelius Omlin presented results from the consensus expert voting on high-risk, non-metastatic hormone-sensitive prostate cancer (nmHSPC) during the 2024/2025 APCCC meeting and queried the audience regarding their preferred management options for select patient scenarios.1

EAU 2026: Update on High-risk Non-metastatic Hormone-sensitive Prostate Cancer

Details

(UroToday.com) The European Association of Urology (EAU) 2026 Annual Congress was host to an advanced prostate cancer session hosted jointly by the Advanced Prostate Cancer Consensus Conference (APCCC) and the EAU. Dr. Isabel Heidegger delivered an update on high-risk, non-metastatic hormone-sensitive prostate cancer (nmHSPC).

EAU 2026: News in the mHSPC Setting, PARP Inhibitors, and More

Details

(UroToday.com) The European Association of Urology (EAU) 2026 Annual Congress was host to a thematic session jointly organized by the Advanced Prostate Cancer Consensus Conference (APCCC) and the EAU. Dr. Karim Fizazi presented an overview of key developments in metastatic hormone-sensitive prostate cancer (mHSPC), focusing on treatment intensification strategies, emerging biomarker-driven therapy selection, and evolving phase III data across several novel therapeutic classes, including PARP inhibitors, radioligand therapy, and AKT inhibition.

EAU 2026: Peri-procedural Prophylactic Antibiotic Use with Gemcitabine Intravesical System Monotherapy: Analysis of Data from SunRISe-1

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a surgical and non-surgical treatment of non-muscle invasive bladder cancer session and a presentation by Dr. Evanguelos Xylinas discussing the SunRISe-1 trial and peri-procedural prophylactic antibiotic use with gemcitabine intravesical system monotherapy. Gemcitabine intravesical system, previously TAR-200, is a first in class intravesical drug-releasing system designed to provide sustained delivery of gemcitabine in the bladder. Gemcitabine intravesical system was recently approved for BCG-unresponsive high risk non muscle invasive bladder cancer with CIS with or without papillary tumors based on the phase 2b SunRISe-1 study.1 Gemcitabine intravesical system is inserted via urinary placement catheter and removed from the bladder via cystoscopy, with removal and new insertion often completed during the same visit. In this analysis of data from SunRISe-1, Dr. Xylinas and colleagues examined the rate of peri-procedural prophylactic antibiotic use and the rate of infectious adverse events in patients who received gemcitabine intravesical system monotherapy.

EAU 2026: Impact of BCG Failure Pattern on Oncologic Outcomes of Intravesical Gemcitabine and Docetaxel in High-Risk NMIBC: A Multicenter European Study

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a surgical and non-surgical treatment of non-muscle invasive bladder cancer session and a presentation by Dr. Pietro Scilipoti discussing a multicenter European study assessing the impact of BCG failure pattern on oncologic outcomes of intravesical gemcitabine and docetaxel in high-risk non-muscle invasive bladder cancer. Intravesical gemcitabine + docetaxel has emerged as a bladder-sparing option for patients with high-risk non-muscle invasive bladder cancer after BCG failure. Whether different BCG failure types affect gemcitabine + docetaxel outcomes remains unclear.

EAU 2026: Reduced Versus Full Dose BCG Maintenance in NMIBC Patients Treated with Full Dose Induction: A Matched Analysis

Details

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a surgical and non-surgical treatment of non-muscle invasive bladder cancer session and a presentation by Dr. Alexandre Zlotta discussing a matched analysis assessing reduced versus full dose BCG maintenance in non-muscle invasive bladder cancer patients treated with full dose induction.